RESOURCES
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial Gallery68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M. Pabst, Rainer Hamacher, Justin Ferdinandus, Benedikt M. Schaarschmidt, Aleksandar Milosevic, Michael Nader, Lale Umutlu, Waldemar Uhl, Anke Reinacher-Schick, Celine Lugnier, David Witte, Marco Niedergethmann, Ken Herrmann, Wolfgang P. Fendler and Jens T. Siveke Abstract The fibroblast activation protein [...]
Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT GalleryFibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT
Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT
Weizhi Xu, Jiayu Cai, Tianxing Peng, Tinghua Meng, Yizhen Pang, Long Sun, Hua Wu, Jingjing Zhang, Xiaoyuan Chen and Haojun Chen Abstract Fibroblast activation protein is overexpressed in the stroma of several cancer types. 18F-fibroblast activation protein inhibitor (FAPI)–74 is a PET tracer with [...]
SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical diagnostics - [68Ga]FAPI-46 and outside-U.S. rights for [18F]FAPI-74 FAP is highly expressed in cancer associated fibroblasts (CAF), which supports [...]
Focus on FAPI Newsletter – Summer 2023
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER Dear FAPI community, It was a busy and exciting summer. In June, SOFIE hosted the 2nd FAP Symposium at the annual SNMMI meeting in Chicago, IL. Representatives from academia and industry spoke to a filled room about the [...]
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study GalleryHead-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Emil Novruzov1, Frederik L Giesel1,2, Yuriko Mori1, Peter L Choyke3, Mardjan Dabir1, Eduards Mamlins1, Dominik Schmitt1, Christina Antke1, Claudio Pinto4, Cristian Soza-Ried5,6, Rene Fernandez5, Horacio Amaral5,6, Vasko Kramer5,6, Leonardo Badinez7 Abstract Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT [...]
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib GalleryComparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Meiqi Wu1, Yanyu Wang2, Qiao Yang1, Xuezhu Wang1, Xu Yang2, Haiqun Xing1, Xinting Sang2, Xiang Li3, Haitao Zhao2, Li Huo4 Abstract Fibroblast activation protein contributes to immunosuppression and resistance to immunotherapies. This study aimed to compare baseline 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT and 18F-FDG [...]
Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis GalleryDiagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
Alessio Rizzo1, Manuela Racca1, Federico Garrou2, Elisabetta Fenocchio3, Luca Pellegrino4, Domenico Albano5, Francesco Dondi5, Francesco Bertagna5, Salvatore Annunziata6, Giorgio Treglia7,8,9 Abstract Various papers have introduced the use of positron emission tomography (PET) with [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in different subtypes of gastric [...]
Fibroblast Activation Protein (FAP) – a target for Imaging and Therapy
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer Targeted Radiopharmaceuticals Summit US (TRP) – Boston, Massachusetts July 25, 2023 Download the presentation
FAP symposium another success at 2023 SNMMI meeting
June 25, 2023 - For the second year in a row, the spotlight shone on FAP at a SOFIE-sponsored symposium drawing a large crowd at the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting held in Chicago, IL. The session, titled “FAP [...]
RLS and SOFIE Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients
LAKE ZURICH, Il. and DULLES, Va. — June 21, 2023, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the US, and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, entered into a strategic partnership for [...]